NMRA

Neumora Therapeutics, Inc. Common Stock (NMRA) | Rumor.io

Neumora Therapeutics

NMRA

Attention (50-day avg)0%

Attention rank (50-day avg)#3,039

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.48

Market capitalization130M

Earnings per share-1.23

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-236.9M

Social

What share of all stock conversation is about NMRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

Neumora Therapeutics, Inc. Common Stock ($NMRA) has been showing early momentum, with traders watching for a potential move to $1.80.
Some analysts are targeting $1.42 as a potential level for Neumora Therapeutics, Inc. Common Stock ($NMRA), while others are watching for a bounce toward $1.70.
The current price of Neumora Therapeutics, Inc. Common Stock ($NMRA) at $0.57715 has been attracting attention, with some traders watching for a potential move to $1.56.

Generated by AI

Sentiment

Of the messages about NMRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.78% +17.36
Bearish	—	—	—	7.22% -17.36

Bullish· Jul 13

Neumora Therapeutics, Inc. (NMRA) is currently trading at a low price point, offering traders a chance to buy in before a potential increase, with some analysts targeting a price of $1.80.
The stock has shown early momentum, indicating a possible move towards $1.64, and some analysts believe this is a setup for a larger price increase.
With the stock building momentum step by step, some analysts are targeting a price of $1.76, and believe that the current price point is a good opportunity to buy in before a potential increase.

Bearish· Jun 16

The company's MDD treatment candidate, NMRA-511, may have a higher placebo rate, which could impact its effectiveness.
The asset's potential for a short squeeze is increasing, with a large number of shares shorted, potentially leading to a price surge.
The asset's pipeline, including potential treatments for AD agitation, schizophrenia, and obesity, may not be sufficient to justify its current valuation.

Generated by AI

Topics

Of the messages about NMRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	42.59%
Earnings	—	0%	0%	2.57%
Analysts	—	0%	0%	7.71%
Controversies	—	0%	0%	0.24%
Macro	—	0%	0%	13.46%
Technical Analysis	—	0%	0%	33.41%

Announcements· Jun 22

NovaRed Mining, now with Kristi Noem on its advisory board, may gain more market attention due to her involvement.
The company's focus on critical minerals and its existing 39,726 acres of land may make it a more attractive investment opportunity.
Governments' increased focus on resource security could lead to more attention and investment in NovaRed Mining.

Technical Analysis· Feb 10

$NMRA has shown strong momentum, with buyers defending levels and pushing higher, potentially leading to continuation.
The stock has broken through key resistance levels, with a surge of +23.35% and +24.69% respectively, confirming powerful momentum ignition.
Technical targets have been set at $3.80 and $3.85, with a catalyst event from the upcoming Guggenheim Summit potentially driving a sustained move.

Generated by AI

Community

Of the messages about NMRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	5.56%	30.44%
Newcomers	—	0%	94.44%	69.56%

Jul 8

New investors are focusing on the momentum and potential for asymmetric setups in Neumora Therapeutics, with some targeting prices of $1.40 and $1.50.
They are also emphasizing the importance of low float momentum and its potential to return quickly, with some investors staying in the stock despite market volatility.
Some newcomers believe Neumora Therapeutics has more room to grow, with one investor holding onto the stock due to long-term conviction and a target price of $1.50.

Generated by AI

News

Neumora Therapeutics COO Aurora disposes of $269,966 in stock

1mo agoInvesting.com

Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock

1mo agoInvesting.com

Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)

Detailed price information for Neumora Therapeutics Inc (NMRA-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clinical data expected in fourth quarter of 2026 and second half of 2026, respectively Joshua Pinto, Ph.D., appointed chief executive officer and member of the Board of Directors Paul L. Berns appointed Executive Chair, continuing to serve as a key strategic leade

1mo agoYahoo Finance

Why Is BioAge Labs Stock Sinking Friday?

2mo agoBenzinga

Also Discussed

Investors talking about NMRA also mention

#	Name	Attention
1	Alto Neuroscience Inc.ANRO	0%new
2	Fathom Holdings Inc.FTHM	0%0
3	Baird Medical Investment Holdings Ltd.BDMD	0%new
4	NewGenIvf Group Limited Class A Ordinary SharesNIVF	0%0
5	Brand Engagement Network Inc.BNAI	0%+0
6	Golden Heaven Group Holdings Ltd.GDHG	0%0
7	Cervomed IncCRVO	0%+0
8	Alignment Healthcare, Inc.ALHC	0%0
9	Vince Holding Corp.VNCE	0%0
10	Enliven Therapeutics, Inc.ELVN	0%0

Neumora Therapeutics, Inc. Common Stock

Healthcare
Biotechnology

Neumora Therapeutics, Inc. Common Stock represents Neumora Therapeutics, a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative conditions. The company applies a precision medicine approach that combines neuroscience, biological insight, and data science to identify and advance therapies aimed at central nervous system targets. Its current pipeline includes candidate medicines in clinical and preclinical development for major depressive disorder, agitation associated with dementia, schizophrenia, Parkinson’s disease, ALS, and obesity-related metabolic disease. Neumora Therapeutics is positioned within the biotechnology sector as a research-driven company centered on novel mechanisms of action for underserved neurological and psychiatric disorders. The common stock reflects the market’s view of a company whose value is tied to progress across this specialized drug development pipeline and the broader demand for new CNS therapies.

Website

Location

260 Arsenal Place

Watertown, MA, 02472

United States

Social

What share of all stock conversation is about NMRA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 13

Neumora Therapeutics, Inc. Common Stock ($NMRA) has been showing early momentum, with traders watching for a potential move to $1.80.
Some analysts are targeting $1.42 as a potential level for Neumora Therapeutics, Inc. Common Stock ($NMRA), while others are watching for a bounce toward $1.70.
The current price of Neumora Therapeutics, Inc. Common Stock ($NMRA) at $0.57715 has been attracting attention, with some traders watching for a potential move to $1.56.

Generated by AI

Sentiment

Of the messages about NMRA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	92.78% +17.36
Bearish	—	—	—	7.22% -17.36

Bullish· Jul 13

Neumora Therapeutics, Inc. (NMRA) is currently trading at a low price point, offering traders a chance to buy in before a potential increase, with some analysts targeting a price of $1.80.
The stock has shown early momentum, indicating a possible move towards $1.64, and some analysts believe this is a setup for a larger price increase.
With the stock building momentum step by step, some analysts are targeting a price of $1.76, and believe that the current price point is a good opportunity to buy in before a potential increase.

Bearish· Jun 16

The company's MDD treatment candidate, NMRA-511, may have a higher placebo rate, which could impact its effectiveness.
The asset's potential for a short squeeze is increasing, with a large number of shares shorted, potentially leading to a price surge.
The asset's pipeline, including potential treatments for AD agitation, schizophrenia, and obesity, may not be sufficient to justify its current valuation.

Generated by AI

Topics

Of the messages about NMRA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	42.59%
Earnings	—	0%	0%	2.57%
Analysts	—	0%	0%	7.71%
Controversies	—	0%	0%	0.24%
Macro	—	0%	0%	13.46%
Technical Analysis	—	0%	0%	33.41%

Announcements· Jun 22

NovaRed Mining, now with Kristi Noem on its advisory board, may gain more market attention due to her involvement.
The company's focus on critical minerals and its existing 39,726 acres of land may make it a more attractive investment opportunity.
Governments' increased focus on resource security could lead to more attention and investment in NovaRed Mining.

Technical Analysis· Feb 10

$NMRA has shown strong momentum, with buyers defending levels and pushing higher, potentially leading to continuation.
The stock has broken through key resistance levels, with a surge of +23.35% and +24.69% respectively, confirming powerful momentum ignition.
Technical targets have been set at $3.80 and $3.85, with a catalyst event from the upcoming Guggenheim Summit potentially driving a sustained move.

Generated by AI

Community

Of the messages about NMRA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	5.56%	30.44%
Newcomers	—	0%	94.44%	69.56%

Jul 8

New investors are focusing on the momentum and potential for asymmetric setups in Neumora Therapeutics, with some targeting prices of $1.40 and $1.50.
They are also emphasizing the importance of low float momentum and its potential to return quickly, with some investors staying in the stock despite market volatility.
Some newcomers believe Neumora Therapeutics has more room to grow, with one investor holding onto the stock due to long-term conviction and a target price of $1.50.

Generated by AI

Neumora Therapeutics

Social

Jul 13

Bullish· Jul 13

Bearish· Jun 16

Announcements· Jun 22

Technical Analysis· Feb 10

Jul 8

Neumora Therapeutics COO Aurora disposes of $269,966 in stock

Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock

Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Why Is BioAge Labs Stock Sinking Friday?

Also Discussed

Neumora Therapeutics, Inc. Common Stock

Company Information

Location

Neumora Therapeutics COO Aurora disposes of $269,966 in stock

Neumora Therapeutics COO Daljit Aurora sells $431,674 in stock

Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Celcuity (CELC) and Parabilis Medicines, Inc. (PBLS)

Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Why Is BioAge Labs Stock Sinking Friday?

Also Discussed

Social

Jul 13

Bullish· Jul 13

Bearish· Jun 16

Announcements· Jun 22

Technical Analysis· Feb 10

Jul 8